Hikma Pharmaceuticals
LSE:HIK Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 22 Fair Values set on narratives written by author
AN
Consensus Narrative from 10 Analysts
R&D Investments And Xellia Acquisition Will Expand Product Pipeline And Revenue Prospects
Key Takeaways Strategic R&D investments and the acquisition of Xellia are expected to enhance Hikma's product pipeline, manufacturing capabilities, and revenue growth. Expanding injectables and generics divisions, alongside MENA region investments, are predicted to sustain growth and stabilize margins.
View narrativeUK£24.31
FV
17.5% undervalued intrinsic discount4.84%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
17users have followed this narrative
6 days ago author updated this narrative